What blockbuster pharma minimizes, the courts eventually consolidate.
Liabilities suppressed during a franchise's peak years — unwarned side effects, undisclosed tax disputes — resurface years later as consolidated multidistrict litigations and nine-figure securities settlements.
The same conclusion keeps arriving from across the workspace's research — 2 topics independently instantiate this theme. Filter the evidence by where it came from:
An undisclosed tax dispute from peak years resurfaced as a securities settlement stacked on the live $10.7 billion Tax Court case.
Vision-loss risks allegedly minimized during the drugs' peak growth years are resurfacing as a consolidated class-wide MDL against both manufacturers.
Thousands of GI-injury claims against the GLP-1 blockbusters are consolidating into a single multidistrict litigation, the exact pattern of suppressed blockbuster liabilities resurfacing years later as consolidated MDLs.